| Date Filed | Type | Description |
| 08/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/08/2023 |
4
| Greene Barry E (President and CEO) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 195,000 options to buy
@ $85.82, valued at
$16.7M
|
|
| 08/07/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 10.6% stake in Sage Therapeutics, Inc. |
| 06/16/2023 |
4
| Federer Jessica (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/16/2023 |
4
| Barrett Elizabeth (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/16/2023 |
4
| FRATES JAMES M (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/16/2023 |
4
| JONAS JEFFREY M (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/16/2023 |
4
| PAUL STEVEN M (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/16/2023 |
4
| Germano Geno J (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/16/2023 |
4
| Golumbeski George (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/16/2023 |
4
| STARR KEVIN P (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/16/2023 |
4
| COLA MICHAEL F (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $56.1, valued at
$561k
|
|
| 06/07/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/11/2023 |
4
| Barrett Elizabeth (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Bought 1,000 shares
@ $50.5, valued at
$50.5k
|
|
| 05/02/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/17/2023 |
3
| Federer Jessica (Director) has filed a Form 3 on Sage Therapeutics, Inc. |
| 03/17/2023 |
4
| Federer Jessica (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 19,894 options to buy
@ $43.64, valued at
$868.2k
|
|
| 03/17/2023 |
4
| IGUCHI KIMI (CFO & Treasurer) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Exercised 3,000 options to buy
@ $1.36, valued at
$4.1k
|
|
| 03/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/23/2023 |
4
| IGUCHI KIMI (CFO & Treasurer) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Exercised 750 options to buy
@ $1.36, valued at
$1k
Exercised 250 options to buy
@ $1.36, valued at
$340 |
|
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 11% stake in SAGE THERAPEUTICS INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 8.2% stake in Sage Therapeutics Inc. |
| 02/07/2023 |
4
| JONAS JEFFREY M (Director) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 5,100 shares
@ $0
Paid exercise price by delivering 1,427 shares
@ $44.16, valued at
$63k
|
|
| 02/07/2023 |
4
| Robichaud Albert (Chief Scientific Officer) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 3,375 shares
@ $0
Paid exercise price by delivering 1,127 shares
@ $44.16, valued at
$49.8k
|
|
| 02/07/2023 |
4
| IGUCHI KIMI (CFO & Treasurer) has filed a Form 4 on Sage Therapeutics, Inc.|
Txns:
| Granted 2,850 shares
@ $0
Paid exercise price by delivering 914 shares
@ $44.16, valued at
$40.4k
|
|
|